merged_africa-snakebite-treatment-access.txt
<other>Analyzing the article, I extract facts directly from the text to answer each question verbatim without additional commentary.</other>
<question_number>1</question_number>
<answer>Venom-induced local tissue necrosis from cytotoxic components combined with delayed, inadequate antivenom treatment.</answer>
<question_number>2</question_number>
<answer>Because venom toxin compositions vary regionally, antivenom produced in India—tailored to local snake toxins—does not neutralize the toxins of Kenyan puff adders.</answer>
<question_number>3</question_number>
<answer>Neurotoxins (from cobras and mambas) and hemotoxins (from puff adders) coupled with antivenom limitations from species‐specific, outdated production methods.</answer>
<question_number>4</question_number>
<answer>N/A</answer>
<question_number>5</question_number>
<answer>Rainy season flooding and hot, dry season foraging drive snakes into rural homes and farmlands, increasing risks for farmers, migrant workers, and children in substandard housing.</answer>
<question_number>6</question_number>
<answer>Short, erect front fangs; highly potent neurotoxic venom causing rapid paralysis; and an agile, swift striking behavior enabled by its long body and distinctive head posture.</answer>
<question_number>7</question_number>
<answer>The need for cold storage delays effective antivenom delivery in under-resourced settings, pushing treatment beyond the critical six-hour window and worsening outcomes for pregnant victims.</answer>
<question_number>8</question_number>
<answer>They can exacerbate injury—tourniquets and traditional remedies hinder blood flow, intensifying tissue necrosis and leading to amputations in the context of treatment delays.</answer>